Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ:GLUE
Want to see GLUE full AI Analyst Report?
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $1.59B. The enterprise value is $1.10B.
Market Cap$1.59B
Enterprise Value$1.10B
Share Statistics
Monte Rosa Therapeutics has 84,479,416 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,479,416
Owned by Insiders10.02%
Owned by Institutions57.33%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -13.56%.
Return on Equity (ROE)-0.17
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-13.56%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee870.93K
Profits Per Employee-272.01K
Employee Count142
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is ―. Monte Rosa Therapeutics’s PEG ratio is 0.64.
PE Ratio―
PS Ratio10.53
PB Ratio5.59
Price to Fair Value5.59
Price to FCF-47.37
Price to Operating Cash Flow-84.01
PEG Ratio0.64
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 123.67M and earned -38.63M in profits. Earnings per share was -0.46.
Revenue123.67M
Gross Profit115.32M
Operating Income-54.21M
Pretax Income-39.72M
Net Income-38.63M
EBITDA-45.85M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was -14.68M and capital expenditures -4.98M, giving a free cash flow of -19.66M billion.
Operating Cash Flow-14.68M
Free Cash Flow-19.66M
Free Cash Flow per Share-0.23
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change373.80%
50-Day Moving Average17.99
200-Day Moving Average14.63
Relative Strength Index (RSI)50.38
Average Volume (3m)785.87K
Important Dates
Monte Rosa Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of 6.12, with Debt / Equity ratio of 7.48%
Current Ratio6.12
Quick Ratio6.12
Debt to Market Cap0.03
Net Debt to EBITDA1.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid -1.10M in taxes.
Income Tax-1.10M
Effective Tax Rate0.03
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is -26.43, with an EV/FCF ratio of -44.07.
EV to Sales9.80
EV to EBITDA-26.43
EV to Free Cash Flow-44.07
EV to Operating Cash Flow-53.16
Balance Sheet
Monte Rosa Therapeutics has $666.22M in cash and marketable securities with $39.06M in debt, giving a net cash position of $627.16M billion.
Cash & Marketable Securities$666.22M
Total Debt$39.06M
Net Cash$627.16M
Net Cash Per Share$7.42
Tangible Book Value Per Share$2.81
Margins
Gross margin is 95.28%, with operating margin of -43.83%, and net profit margin of -31.23%.
Gross Margin95.28%
Operating Margin-43.83%
Pretax Margin-32.12%
Net Profit Margin-31.23%
EBITDA Margin-37.08%
EBIT Margin-43.83%
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $32.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.80
Price Target Upside65.82% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-73.07%
EPS Growth Forecast-2335.85%